Related references
Note: Only part of the references are listed.Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1
Hye-Kyung Park et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach
Chao Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma
Zhenzhen Liu et al.
CELL CHEMICAL BIOLOGY (2019)
Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications
Yuemin Bian et al.
AAPS JOURNAL (2018)
Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis
Yann Ayotte et al.
CHEMMEDCHEM (2018)
Hsp90 interacts with multiple dengue virus 2 proteins
Kanjana Srisutthisamphan et al.
SCIENTIFIC REPORTS (2018)
HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons
Sarah Kishinevsky et al.
NATURE COMMUNICATIONS (2018)
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
Amber Shatzer et al.
LEUKEMIA & LYMPHOMA (2017)
Identification of HSP90 inhibitors as a novel class of senolytics
Heike Fuhrmann-Stroissnigg et al.
NATURE COMMUNICATIONS (2017)
A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists
He Peng et al.
SCIENTIFIC REPORTS (2017)
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors
Magdalena Korczynska et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Targeting Hsp90 in Non-Cancerous Maladies
Mark R. Woodford et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Twenty years on: the impact of fragments on drug discovery
Daniel A. Erlanson et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model
Eva Tonsing-Carter et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis
Tali Voloshin et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Ligand deconstruction: Why some fragment binding positions are conserved and others are not
Dima Kozakov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
Coumaran Egile et al.
MOLECULAR CANCER THERAPEUTICS (2015)
TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Shuichi Ohkubo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Muhammad Wasif Saif et al.
CLINICAL CANCER RESEARCH (2014)
Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs
Chisako Kanamaru et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2014)
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Duncan E. Scott et al.
BIOCHEMISTRY (2012)
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
Andrew J. Woodhead et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism
Xiaoping Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction
Tao Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors
Tzu-Yin Lin et al.
EXPERIMENTAL HEMATOLOGY (2008)
4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer
Paul A. Brough et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity
Srinivas R. Kasibhatla et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
Jie Ge et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: An orally bioavailable heat shock protein 90 modulator
G Kaur et al.
CLINICAL CANCER RESEARCH (2004)
Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups
P Ertl
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2003)
Share Paper
